Evidence map›Paper›PMID 41030685›Full record

ArticleACS applied nano materials2025

Prostate-Specific Membrane Antigen (PSMA)-Directed Dendrimer-Camptothecin Conjugate for Targeted Treatment of Prostate Cancer.

Anubhav Dhull, Anunay James Pulukuri, Aqib Iqbal Dar, Nina Julia Palmer, Joan Castaneda Gonzalez, Anu Rani, Rishi Sharma, Clifford E Berkman, Anjali Sharma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied nano materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Enhancing Cytosolic Internalization of [International journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anubhav DhullDepartment of Chemistry, College of Arts and Sciences, Washington State University, Pullman, Washington 99164, United States.
Anunay James PulukuriDepartment of Chemistry, College of Arts and Sciences, Washington State University, Pullman, Washington 99164, United States.
Aqib Iqbal DarDepartment of Chemistry, College of Arts and Sciences, Washington State University, Pullman, Washington 99164, United States.
Nina Julia PalmerDepartment of Chemistry, College of Arts and Sciences, Washington State University, Pullman, Washington 99164, United States.
Joan Castaneda GonzalezDepartment of Chemistry, College of Arts and Sciences, Washington State University, Pullman, Washington 99164, United States.
Anu RaniDepartment of Chemistry, College of Arts and Sciences, Washington State University, Pullman, Washington 99164, United States.
Rishi SharmaDepartment of Chemistry, College of Arts and Sciences, Washington State University, Pullman, Washington 99164, United States.
Clifford E BerkmanDepartment of Chemistry, College of Arts and Sciences, Washington State University, Pullman, Washington 99164, United States.ORCID 0000-0003-2544-5252
Anjali SharmaDepartment of Chemistry, College of Arts and Sciences, Washington State University, Pullman, Washington 99164, United States.ORCID 0000-0003-0748-3001

Funding

Targeted nanotherapies for the treatment of prostate cancerR21CA286235 · NCI · WASHINGTON STATE UNIVERSITY · PI SHARMA, ANJALI · 2024 to 2024
$407k
NCI NIH HHS R21 CA286235
6 · The paper itself

Abstract

Prostate cancer (PC) remains a major global health challenge, particularly in its advanced, treatment-resistant form. Although Camptothecin (Campto) is a potent topoisomerase I inhibitor with strong antiproliferative and pro-apoptotic activity, its clinical utility is limited by poor aqueous solubility, instability, and systemic toxicity. To address these challenges, we developed a prostate-specific membrane antigen (PSMA)-targeted dendrimer-Camptothecin conjugate (PD-Campto-CTT1298) that improves drug solubility, enables receptor-mediated uptake, and enhances therapeutic effects. This platform was synthesized by conjugating Campto and a high-affinity PSMA ligand (CTT1298) to a generation-4 hydroxyl-terminated PAMAM dendrimer (PD) via copper-catalyzed and strain-promoted azide-alkyne cycloaddition reactions. The resulting conjugate exhibited high aqueous solubility, formulation stability, and efficient drug loading.

Indexed as

camptothecinclick chemistryPAMAM dendrimerprostate cancertargeted drug delivery

Identifiers

PMID41030685
PMCPMC12478556

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.